Key Points {#FPar1}
==========

There is currently no consensus on how gentamicin should be dosed in obese and morbidly obese individuals.In this study with 20 morbidly obese individuals and eight non-obese individuals with body weights from 53 to 221 kg and normal renal function, we found that body weight is an important determinant of gentamicin clearance and central volume of distribution in a two-compartmental model.We introduce a novel dose regimen to be used in obese patients with a normal renal function, which is based on an allometric 'dose weight' \[calculated as 70 × (total body weight/70)^0.73^\] to obtain similar exposure across all body weights up to 215 kg.

Introduction {#Sec1}
============

Gentamicin is an aminoglycoside antibiotic that is frequently used in severe life-threatening infections. Aminoglycosides are widely used antibiotics, predominantly used empirically to expand Gram-negative coverage, although emerging aminoglycoside resistance is a widely recognized threat \[[@CR1]\]. Clearly, a favorable outcome can only be achieved with gentamicin if adequate exposure is ensured. For aminoglycosides, a distinct relation between aminoglycoside blood concentrations and both efficacy and toxicity has been reported \[[@CR2]\]. Many studies, mostly in vitro and animal in vivo studies, have shown that both the gentamicin maximum (peak) concentrations (*C*~max~) relative to the minimal inhibitory concentration (MIC) (*C*~max~/MIC) and the 24-h free drug area under the concentration--time curve (*f*AUC~24~)/MIC is predictive for effectiveness \[[@CR3]--[@CR5]\]. While these pharmacodynamic indices are to some extent correlated, the general consensus now is that *f*AUC~24~/MIC is the primary pharmacodynamic index for aminoglycosides driving efficacy \[[@CR2], [@CR6], [@CR7]\]. Aminoglycoside (nephro- and oto-) toxicity correlates with minimum (trough) concentrations (*C*~min~) \> 1 mg/L \[[@CR8]\].

Obesity and morbid obesity, commonly defined as a body mass index (BMI) of \>  40 kg/m^2^, is known to influence different pharmacokinetic parameters such as clearance and volume of distribution, even though exact quantification is still warranted for many drugs \[[@CR9], [@CR10]\]. This is especially true for gentamicin, which in normal weight patients is typically dosed on a mg/kg basis \[[@CR11]\]. For obese individuals, several dosing strategies have been proposed, mostly based on alternative body size descriptors such as adjusted body weight (ABW). ABW uses a scaling factor for correcting for limited drug diffusion in adipose body tissue \[[@CR12]\]. Several studies found that with increasing body weight, ABW was predictive for changes in aminoglycoside volume of distribution \[[@CR12]--[@CR16]\] and therefore for *C*~max~. More recently, lean body weight (LBW; represents fat-free mass consisting of bone tissue, muscles, organs, and blood volume calculated according to the Janmahasatian formula) was suggested for use in dosing gentamicin, also because of its correlation with volume of distribution \[[@CR17], [@CR18]\]. However, as gentamicin *exposure* drives efficacy, changes in gentamicin clearance are to be taken into account when optimizing drug dosing in the obese. Previous studies report an increase in total body clearance with increasing body weight \[[@CR12]--[@CR14], [@CR16]\], with two studies suggesting that ABW might be a predictive covariate for gentamicin clearance \[[@CR13], [@CR14]\]. However, compared to current practice, the degree of obesity in these studies was limited, with average body weights that do not exceed 100 kg in most studies. Moreover, many studies rely on sparse sampling from therapeutic drug monitoring, in an era where aminoglycosides were typically dosed three times daily, and, as such, many studies obtained only a limited number of samples up to 8 h post infusion. As a consequence, the exact influence of obesity on the pharmacokinetics of gentamicin, especially clearance, remains yet to be quantified across the current body weights that we are facing in the clinic.

In this prospective clinical study, we study the pharmacokinetics of gentamicin in obese and morbidly obese individuals versus non-obese individuals in order to develop a dosing algorithm that can be used across the whole clinical population, and that will lead to similar exposure (area under the concentration--time curve from time zero to 24 h \[AUC~24~\]) and optimal *C*~min~ values (\< 1 mg/L) in obese individuals compared with their non-obese counterparts.

Patients and Methods {#Sec2}
====================

Participants {#Sec3}
------------

Morbidly obese patients (BMI above 40 kg/m^2^ or above 35 kg/m^2^ with co-morbidities) scheduled to undergo laparoscopic bariatric surgery (either a gastric bypass or sleeve gastrectomy) and non-obese healthy volunteers (BMI 18--25 kg/m^2^) were considered for inclusion in this study. Exclusion criteria were a known allergy to aminoglycosides, renal insufficiency (defined as an estimated glomerular filtration rate \[eGFR\] below 60 mL/min based on the Cockcroft-Gault \[CG\] formula with LBW and the Modification of Diet in Renal Disease \[MDRD\] formula for obese and non-obese individuals, respectively) \[[@CR18]--[@CR20]\], pregnancy or breastfeeding, or treatment with potentially nephrotoxic medication in the week before surgery. Before inclusion, participants provided written informed consent. The study was registered in the Dutch Trial Registry (NTR6058), approved by the local human research and ethics committee, and was conducted in accordance with the principles of the Declaration of Helsinki.

Study Procedures and Data Collection {#Sec4}
------------------------------------

Morbidly obese patients received a single gentamicin dose of 5 mg/kg LBW (calculated using the Janmahasatian formula \[[@CR18]\]), administered intravenously in 30 min, 1--2 h prior to induction of anesthesia. We chose a LBW-based dose regimen for obese individuals because the use of total body weight (TBW) was expected to lead to very high doses and because LBW may be a good body size descriptor for gentamicin dosing \[[@CR17]\]. Gentamicin was administered as part of the study protocol, not as part of routine care. Non-obese healthy volunteers received a dose of 5 mg/kg TBW infused over 30 min. Venous blood samples were collected 5, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after end of infusion. Blood samples (3 mL) were collected in lithium-heparin tubes, centrifuged at 1900*g* for 5 min, and stored at − 80 °C until analysis.

For each patient, data were recorded on body weight, body length, sex, age, and self-reported history/duration of obesity (estimation of number of years the patient fulfils definition of morbid obesity). Serum creatinine was measured and 24-h urine was collected on the study day, with which the glomerular filtration rate (GFR) was calculated. In addition, serum creatinine-based GFR estimates were calculated for each patient using either the CG (using LBW for obese and TBW for non-obese individuals, as described before \[[@CR19]\]) or MDRD formula (de-indexed for body surface area \[BSA\]).

For the population pharmacokinetic analysis, BSA was calculated for each individual using the Du Bois--Du Bois formula \[[@CR21]\]. ABW was calculated with Eq. ([1](#Equ1){ref-type=""}), as published previously \[[@CR12]\]:$$\documentclass[12pt]{minimal}
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Drug Assay {#Sec5}
----------

Total gentamicin plasma concentrations were quantified using a commercially available, validated immuno-assay kit (Roche Diagnostics GmbH, Mannheim, Germany). The lower limit of quantification (LLOQ) of this assay was 0.4 mg/L and the lower limit of detection (LOD) was 0.3 mg/L.

Non-Compartmental Statistical Analysis {#Sec6}
--------------------------------------

Individual gentamicin AUC~24~ was calculated using the trapezoidal rule. *C*~max~ and *C*~min~ were defined as the gentamicin plasma concentration measured at 1 and 24 h after start of infusion, respectively. Categorical data were analyzed by Chi-square test. Continuous data are shown as mean ± standard deviation (SD) and analyzed by *t*-test when normally distributed or as median ± interquartile range (IQR) and analyzed by Mann-Whitney--Wilcoxon test when not normally distributed. Statistics were performed using R (version 3.4.4) \[[@CR23]\]. Differences with a *p*-value \< 0.05 were considered statically significant.

Population Pharmacokinetic Analysis and Validation {#Sec7}
--------------------------------------------------

Gentamicin concentrations in both obese and non-obese were analyzed using non-linear mixed-effect modelling (NONMEM^®^ version 7.3 \[Icon Development Solutions, Ellicott City, MD, USA\], Pirana^®^ version 2.9.7, and PsN \[Perl-speaks-NONMEM\] version 4.6.0) \[[@CR24], [@CR25]\]. Concentrations below LLOQ (*n* = 24/280, 8.6%) were incorporated in the analysis using the M3 method \[[@CR26]\].

Model development was done in three stages: (1) definition of the structural model; (2) development of the statistical model; and (3) a covariate analysis. In these steps, discrimination between models was made by comparing the objective function value (OFV, defined by -- 2 log likelihood). A *p*-value of \< 0.05, representing a decrease of 3.84 in the OFV value between nested models, was considered statistically significant. Furthermore, goodness-of-fit plots, differences in parameter estimates' coefficients of variation, or individual plots were evaluated to discriminate between models. Inter-individual variability on parameter estimates was assumed to be log-normally distributed in the population. For residual variability, e.g., resulting from assay errors, model misspecifications or intra-individual variability, a combined additive and proportional error model was investigated.

For the covariate analysis, potentially relevant relations between covariates and pharmacokinetic parameters were visually explored by plotting inter-individual variability estimates independently against the individual covariate values. Covariates that were explored in this manner were TBW, LBW, ABW, BMI, age, sex, GFR, and eGFR (BSA-corrected MDRD or CG using LBW). After visual inspection, potential covariates were separately entered into the model. Continuous covariates were introduced using Eq. [2](#Equ2){ref-type=""} for exponential relations and Eq. [3](#Equ3){ref-type=""} for linear relations:$$\documentclass[12pt]{minimal}
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                \begin{document}$$P_{\text{i}} = P_{\text{p}} \times \left( {1 + Z \times \left( {{\text{COV}} - {\text{COV}}_{\text{standard}} } \right) } \right)$$\end{document}$$where *P*~i~ and *P*~p~ represent individual and population parameter estimates, COV represents the covariate, COV~standard~ represents a population standardized (e.g., 70 kg for TBW) or median value for the covariate, *X* represents the exponent for a power function, and *Z* is the slope parameter for the linear covariate relationship. Categorical covariates were entered into the model by calculating a separate pharmacokinetic parameter for each category of the covariate. If applicable, it was evaluated whether the inter-individual variability in the parameter concerned decreased upon inclusion of the covariate and whether the plot of the inter-individual variability versus the covariate improved. Additionally, goodness of fit was assessed as described earlier. Using forward inclusion (*p* \< 0.05, OFV decrease \> 3.8) and backward deletion (*p* \< 0.001, OFV increase \> 10.8), inclusion of the covariate in the final model was justified.

Internal model validation was performed using prediction-corrected visual predictive checks (pcVPCs) and bootstrap resampling analysis \[[@CR27], [@CR28]\]. More details of the methods used for model development and internal validation can be found in the Electronic Supplementary Material (ESM).

Model-Based Simulations to Guide Drug Dosing {#Sec8}
--------------------------------------------

Using the final model, Monte Carlo simulations were performed in 10,000 patients in a weight range of 50--215 kg for different dose regimens, which included 5 and 7 mg/kg TBW, 5 and 8 mg/kg LBW, 5 mg/kg ABW, and a novel dose nomogram based on the final pharmacokinetic model. In every simulation, gentamicin was administered intravenously over 30 min with 24 h of follow-up. Values for LBW, IBW, and ABW were obtained by resampling data stratified on TBW from the National Health and Nutrition Examination Survey (NHANES) database containing demographic data from a large representative cohort of adults from the USA from 1999 to 2016 \[[@CR29]\]. Simulations aimed to target a similar exposure (AUC~24~) to that in non-obese individuals (\< 100 kg) receiving gentamicin in the standard dose of 5 mg/kg TBW and non-toxic *C*~min~ values (\< 1 mg/L) in obese individuals.

Results {#Sec9}
=======

Patients and Data {#Sec10}
-----------------

Table [1](#Tab1){ref-type="table"} shows the patient characteristics of the 20 morbidly obese patients (median body weight 148.8 kg, range 109--221 kg) and eight non-obese individuals (median body weight 72.9 kg, range 53--86 kg) that were included in this study. For each individual, ten samples were obtained, yielding 280 gentamicin plasma concentrations in total. Figure [1](#Fig1){ref-type="fig"} shows the measured plasma concentrations versus time after start of infusion. Both AUC~24~ and *C*~max~ were lower in morbidly obese individuals administered 5 mg/kg LBW than in non-obese individuals administered 5 mg/kg TBW (AUC~24~: 43.7 ± 9.7 vs. 68.7 ± 9.5 mg h/L, *p* \< 0.001; *C*~max~: 8.6 ± 2.2 vs. 17.8 ± 2.6 mg/L, *p* \< 0.001). *C*~min~ levels in all individuals were \< 0.5 mg/L.Table 1Patient characteristicsCharacteristicMorbidly obese (*n* = 20)Non-obese (*n* = 8)*p* valueSex (% male)50%50%1.00Total body weight (kg)148.8 ± 25.9 \[109--221\]72.9 ± 7.9 \[53--86\]\< 0.001Lean body weight (kg)76.5 ± 25.4 \[55--99\]54.0 ± 17.9 \[37--68\]0.003BMI (kg/m^2^)44.4 ± 8.3 \[37--65\]21.8 ± 2.2 \[18--24\]\< 0.001Age (years)40.5 ± 12.5 \[19--54\]22.0 ± 3.5 \[19--50\]0.004Glomerular filtration rate (mL/min)171.9 ± 70.0 \[110--230\]123.7 ± 54.8 \[91--170\]0.013Gentamicin dose (mg)380 ± 120.0 \[280--480\]360 ± 30.0 \[240--440\]0.466Data are given as median ± interquartile range \[range\], unless stated otherwise*BMI* body mass indexFig. 1Observed gentamicin plasma concentrations (mg/L) versus time after start of infusion (h) for morbidly obese (receiving 5 mg/kg lean body weight, black lines) and non-obese (receiving 5 mg/kg total body weight, grey lines) individuals. Each line represents one individual

Population Pharmacokinetic Model and Validation {#Sec11}
-----------------------------------------------

A two-compartment model with a combined residual error model best described the data, with inter-individual variability on central volume of distribution (*V*~c~) and clearance (Table [2](#Tab2){ref-type="table"}).Table 2Population pharmacokinetic parameters of the base model and final modelParameterBase model (%CV)Final model (%CV)Bootstrap final model (*n* = 939/1000 successful runs) \[mean (95% CI)\]*V*~c~ (L)23.3 (10.0)*V*~c~ = *V*~c70kg~ × (TBW/70)^*X*^ *V*~c70kg~ (L)11.9 (8.8)11.9 (10.3--13.5) *X*1.25 (10.8)1.26 (1.06--1.46)CL (L/min)0.130 (5.7)CL = CL~70kg\ ×~ (TBW/70)^*Z*^ CL~70kg~ (L/min)0.0892 (5.6)0.0892 (0.0815--0.0969) *Z*0.729 (9.6)0.735 (0.572--0.898)*V*~p~ (L)7.06 (8.0)7.29 (5.7)7.33 (6.32--8.35)*Q* (L/min)0.0812 (17.4)0.0848 (8.2)0.0873 (0.0541--0.121)IIV (%) *V*~c~^a^49.6 (11.6)19.2 (16.6)18.9 (7.98--25.7) CL^a^32.0 (16.4)18.1 (5.0)17.6 (11.3--22.2) Covariance IIV *V*~c~--CL0.03160.0302 (0.00894--0.0514)Proportional error^b^0.156 (10.8)0.159 (8.2)0.157 (0.125--0.190)Additive error (mg/L)^b^0.221 (10.2)0.206 (8.4)0.204 (0.160--0.247)OFV329.4232.9223.0Parameter estimates are shown with standard error of estimate reported as %CV*CI* confidence interval, *CL* clearance from the central compartment, *CL*~*70**kg*~ clearance from the central compartment for an individual weighing 70 kg, *CV* coefficient of variation, *IIV* inter-individual variation, *OFV* objective function value, *Q* intercompartmental clearance, *TBW* total body weight, *V*~*c*~ central volume of distribution, *V*~*c70**kg*~ central volume of distribution for an individual weighing 70 kg, *V*~*p*~ peripheral volume of distribution, *X* exponent for a power function on Vc, *Z* exponent for a power function on CL^a^ Eta-shrinkage for IIV in the final model is 4% (CL) and 7% (*V*~c~)^b^ Estimates of residual error terms are reported as standard deviation

The covariate analysis showed that TBW was the most predictive covariate for both *V*~c~ and clearance (*p* \< 0.001 for both). Figure [2](#Fig2){ref-type="fig"} shows the individual estimates for clearance and *V*~c~ versus TBW of the included obese and non-obese individuals. Plots for the other covariates are shown in the ESM (Fig. S1). Implementation of TBW with a power function on *V*~c~ and clearance led to a reduction in unexplained inter-individual variability from 49.6% to 18.5% for *V*~c~ and from 32.2% to 17.4% for clearance. In addition, OFV was found to reduce by 44.4 (*p* \< 0.001) and 30.2 (*p* \< 0.001) points for *V*~c~ and clearance, respectively. Implementation of LBW or ABW on *V*~c~ was inferior to TBW, even though these covariates significantly improved the base model as well, albeit less convincingly than TBW, with smaller OFV drops (-- 19.1 and -- 17.3 for LBW on *V*~c~ and clearance, -- 18.8 and -- 21.2 for ABW on *V*~c~ and clearance, respectively) and poorer goodness-of-fit diagnostics (data not shown). While no influence of MDRD or CG was visible, GFR seemed to slightly influence clearance, although this correlation disappeared after inclusion of TBW on clearance.Fig. 2Individual values (*n* = 28) for **a** central volume of distribution (in L) and **b** clearance (in L/min) versus total body weight from the base model. The black line represents the covariate relation as implemented in the final model (Table [2](#Tab2){ref-type="table"}). *CL* clearance, *TBW* total body weight, *V*~c~ central volume of distribution

According to the final model (Table [2](#Tab2){ref-type="table"}), *V*~c~ and clearance are best described using Eqs. ([4](#Equ4){ref-type=""}) and ([5](#Equ5){ref-type=""}):$$\documentclass[12pt]{minimal}
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                \begin{document}$${\text{CL}}_{i} = \, 0.0 8 9 { }\left[ {0.0 8 2 { }{-} \, 0.0 9 7} \right] \, \times \, \left( {{\text{TBW}}_{i} / 70} \right)^{{0. 7 3 { }[0. 5 7 { }{-} \, 0. 90]}}$$\end{document}$$where V~c,*i*~ and CL~*i*~ are the *V*~c~ and clearance of the *i*th individual, respectively. TBW~*i*~ is the TBW of the *i*th individual. 95% confidence intervals (CIs) based on the bootstrap resampling (Table [2](#Tab2){ref-type="table"}) are shown in brackets.

The parameter estimates of the final model are shown in Table [2](#Tab2){ref-type="table"}. Goodness-of-fit plots of the final model are presented in the ESM (Fig. S2).

For internal validation, stratified pcVPCs for obese and non-obese individuals are shown in Fig. [3](#Fig3){ref-type="fig"} and show good predictive performance for both groups where CIs for the median and 2.5th and 97.5th percentiles of observed and model-simulated data are in good agreement. The results of the bootstrap analysis confirmed the model parameters and robustness of the model and are presented in Table [2](#Tab2){ref-type="table"}.Fig. 3Prediction-corrected visual predictive checks of the final model for non-obese (upper left panel) and obese (upper right panel) individuals. The observed concentrations are shown as black circles; the median and 2.5th and 97.5th percentiles of the observed data are shown as the solid and lower and upper dashed lines, respectively. The gray shaded areas show the 95% confidence intervals of the median (dark gray) and 2.5th and 97.5th percentiles (light gray) of the simulated concentrations (*n* = 1000) based on the original dataset. Lower panels show the observed proportion below the limit of quantification (black dots), where shaded areas represent the 95% confidence interval of the proportion based on the simulated concentrations (*n* = 1000). *LOQ* limit of quantification

Model-Based Simulations with Different Dose Regimens {#Sec12}
----------------------------------------------------

Figure [4](#Fig4){ref-type="fig"} shows the median and 95% CI for the AUC~24~ (upper panel) and *C*~min~ (lower panel) with different dosing regimens for individuals with a weight range of 50--215 kg based on Monte Carlo simulations. The median AUC~24~ in non-obese individuals (\< 100 kg) receiving gentamicin at a commonly prescribed dose of 5 mg/kg TBW represents the target for gentamicin exposure (depicted as horizontal dashed line.Fig. 4Boxplots (median and 95% confidence interval) representing gentamicin AUC~24~ (upper panel) and *C*~min~ (lower panel) for different weight categories based on Monte Carlo simulations with six different TBW-, LBW- (calculated with the Janmahasatian formula \[[@CR18]\]), and ABW \[calculated as IBW + 0.4 × (TBW -- IBW)\]-based dosing regimens (*n* = 10,000 per regimen). The proposed nomogram is based on a 'dose weight' calculated as 70 × (TBW/70)^0.73^ (shown in Table [3](#Tab3){ref-type="table"}). The dashed line represents the median value of 5 mg/kg TBW in the \< 100 kg group as a target reference for AUC~24~ (upper panel) or 1 mg/L as a target reference for *C*~min~ (lower panel). *ABW* adjusted body weight, *AUC*~*24*~ area under the concentration--time curve from time zero to 24 h, *C*~*min*~ minimum (trough) concentration, *LBW* lean body weight, *TBW* total body weight

Figure [4](#Fig4){ref-type="fig"} (upper panel) illustrates that a dose based on LBW (i.e., 5 or 8 mg/kg LBW) leads to a decrease in AUC~24~ with increasing body weight. In contrast, dosing based on TBW (depicted for 5 and 7 mg/kg) leads to higher AUC~24~ values with increasing body weight. The use of ABW (5 mg/kg) results in a similar AUC~24~ across body weights as that of the reference \< 100 kg group, with a slight trend towards a decreased AUC~24~ with increasing body weight. When a dose regimen based the equation for clearance of the final model \[i.e., an allometric 'dose weight', which is calculated as 70 × (TBW/70)^0.73^; Table [3](#Tab3){ref-type="table"}\] is used, a similar AUC~24~ to that of the reference group is yielded across all weight ranges up to 215 kg.Table 3Proposed dose nomogram \[based on a 5 mg/kg 'dose weight', calculated as 70 × (TBW/70)^0.73^\] for selecting the gentamicin dose in obese individuals with normal renal function (\> 60 mL/min)TBW (kg)Gentamicin dose (mg)\< 100Dose on TBW100--120480120--140560140--160600160--180680180--200760200--220800*TBW* total body weight

For all dose regimens and weight ranges, gentamicin *C*~min~ values were below the limit of 1 mg/L (Fig. [4](#Fig4){ref-type="fig"}, lower panel). Results for *C*~max~ are shown in Fig. S3 in the ESM, showing that a TBW-based dose regimen yields similar *C*~max~ values across body weights.

Discussion {#Sec13}
==========

In this study, we have successfully developed a population pharmacokinetic model for gentamicin based on full pharmacokinetic curves obtained in individuals with body weights ranging from 53 to 221 kg. Our study shows that in obese individuals, both gentamicin clearance and *V*~c~ are significantly influenced by body weight. These findings can be used as guide for dosing in the ever-increasing group of obese and morbidly obese patients.

Our study shows that gentamicin clearance increases with TBW. From the studies investigating the pharmacokinetics of aminoglycosides in obesity \[[@CR12], [@CR14]--[@CR17], [@CR30], [@CR31]\], four papers reported an increase in clearance in obese patients \[[@CR12]--[@CR14], [@CR16]\] and two studies found ABW as a predictive covariate \[[@CR13], [@CR14]\]. In these studies participants were only moderately obese (average body weights around 80--100 kg with SDs around 15--20 kg). Moreover, at the time these studies were conducted, aminoglycosides were typically dosed in regimens of up to three times daily, and as such many studies obtained samples up to 8 h post infusion only, thereby limiting the estimation of gentamicin clearance and the prediction of 24-h exposure and *C*~min~ values. In this respect, we believe that our study is an important addition to the existing literature, since we were able to sample up to 24 h post infusion (instead of 8 h) in a wide range of body weights (53--221 kg) and, combined with using state-of-the-art modelling techniques, we could for the first time accurately assess gentamicin clearance and its covariates in the obese population.

An important question is how the finding that clearance changes with body weight in obese individuals can be explained. The exponent of 0.73 (95% CI 0.57--0.90) we identified for the change with weight is comparable to the value of 0.75 which has been reported as a value that describes the influence of size on clearance in allometry theory \[[@CR32]\]. However, it is debatable whether an increase in weight resulting from obesity can be compared with an increase in weight because of an increase in size \[[@CR32]\]. For other drugs that were studied in obese patients, many show unchanged clearance with increasing weight, even when morbidly obese patients were included \[[@CR33]--[@CR35]\]. The increase in gentamicin clearance with body weight we identify in this study could potentially be explained by a larger GFR in obese individuals and/or an increase in organic cation transporter 2 (OCT2) activity as gentamicin was reported to be a substrate for OCT2 \[[@CR36]\]. With respect to GFR, it is emphasized that in our study only individuals with a GFR \> 60 mL/min were included. In our study, weight was the most important covariate, and after implementation of weight, no additional influence of GFR could be identified, even though the GFR range in our population was large (110--230 mL/min). While this does not preclude GFR being the explanation for the observed increase in gentamicin clearance in the obese, and also for other renally excreted drugs such as cefazoline, no increase in clearance with increasing weight was found when studied in morbidly obese and non-obese individuals \[[@CR35], [@CR37]\]. As such, perhaps the increased activity in OCT2 that was reported in overfed rats and that led to increased gentamicin uptake in renal tubular cells \[[@CR36]\] may be considered as an explanation for the findings of our study. In line with this hypothesis, for metformin, which is known to be secreted by OCT2 in the tubulus, a larger clearance was found in obese adolescents (1.17 L/min) than in non-obese children (0.55 L/min), which was also explained by a higher OCT2-mediated tubular secretion of metformin in obese individuals \[[@CR38]\]. From these results it seems that more basic research is needed to identify the exact cause of our findings.

Furthermore, our study demonstrates that *V*~c~ best correlates with body weight. Earlier studies with aminoglycosides in obese patients found ABW or LBW to correlate with volume of distribution \[[@CR12]--[@CR14], [@CR17], [@CR30]\]. In our study we obtained a large number of samples over a 24-h window, including samples that were taken shortly after infusion (i.e., 5, 30, 60, and 90 min after infusion). This study design allows us to fully describe the pharmacokinetics of gentamicin in detail. Most of the previously published studies were performed with sparse (therapeutic drug monitoring) data with only a few samples taken shortly after infusion and consequently analyzed by non-compartmental analysis, thereby complicating exact estimation of the volume of distribution. While the detailed information resulting from our sampling scheme and advanced modelling strategy justifies the conclusions regarding changes of volume of distribution with weight, the results challenge the common assumption that only limited changes in volume of distribution are to be expected for hydrophilic drugs such as gentamicin. It therefore seems that lipophilicity alone is a poor predictor of how volume of distribution changes with increasing body weight, as was demonstrated in several recent reviews \[[@CR9], [@CR39]\].

Based on the results of our study, we propose administration of gentamicin using a practical dose nomogram (Table [3](#Tab3){ref-type="table"}) that is based on a body weight-derived allometric 'dose weight' \[i.e., 70 × (TBW/70)^0.73^\] and is derived from the allometric relationship between clearance (driving AUC) and TBW (Table [2](#Tab2){ref-type="table"}, Eq. [5](#Equ5){ref-type=""}). Considering *f*AUC~24~/MIC as the primary pharmacodynamic index for aminoglycoside treatment, our dosing nomogram yields a similar gentamicin exposure (AUC~24~) across all weights with all *C*~min~ values \< 1 mg/L (Fig. [4](#Fig4){ref-type="fig"}). In clinical practice, the nomogram can easily be implemented to select the initial gentamicin dosage, after which dose individualization may be employed by estimating the individual's gentamicin clearance. This is typically done using therapeutic drug monitoring (where one or two samples are taken during the β-elimination phase, for instance between 2 and 8 h post infusion) in combination with Bayesian software employed with a suitable population pharmacokinetic model. The population pharmacokinetic model presented in the current paper could be used for this purpose. Alternatively, for example when such software is unavailable, other approaches have been suggested to individualize gentamicin drug treatment \[[@CR7]\].

Figure [4](#Fig4){ref-type="fig"} also illustrates that ABW- and LBW-based dose regimens show trends towards a lower exposure with increasing body weight. Despite these trends across weight, it seems that 8 mg/kg LBW and 5--6 mg/kg ABW could be considered as alternatives for our nomogram because using these doses in the median range of the morbidly obese population leads to rather similar AUC~24~ values. Implementation of LBW, and to a lesser extend ABW, has, however, been hampered by the complexity of the calculations, which is why we came up with our nomogram, as depicted in Table [3](#Tab3){ref-type="table"}.

Some limitations may apply to our results. First, individuals in our study were, besides (some) being overweight, otherwise healthy, relatively young, and had no renal impairment. As a consequence, renal dysfunction in the obese could not be studied, while in non-obese patients gentamicin clearance has been reported to be dependent on renal function \[[@CR40]\]. Also, drug pharmacokinetics have been shown to be influenced by critical illness \[[@CR41]\]. Therefore, further refinement of our model is warranted for use in obese patients with renal impairment, critical illness, and/or older age. Still, we believe that the dose recommendations from the current study can be a valuable starting point for dosing of obese patients with renal impairment or critical illness. Second, in the current study we did not study the pharmacokinetics of gentamicin after significant reduction in body weight following bariatric surgery. It has been shown for the benzodiazepine midazolam that the pharmacokinetics in these individuals are different to those in individuals with the same body weight without a history of obesity \[[@CR42]\]. Third, we did not include individuals with a BMI 25--35 kg/m^2^. However, based on the relationship between TBW and clearance and *V*~c~, as depicted in Fig. [2](#Fig2){ref-type="fig"}, we think it is justified to conclude that the pharmacokinetics will not be any different in these individuals. Last, the obese individuals in our study underwent bariatric surgery during the study procedures, which in theory might influence pharmacokinetics. In our hospital, bariatric surgery is performed laparoscopically, with a short procedure (usually 30--45 min) involving minimal blood loss (usually \< 50 mL). Also, hemodynamics were tightly monitored and regulated during surgery. No major hemodynamic instability was recorded for any of the included individuals in our study. For this reason, we expect that the influence of surgery on the pharmacokinetics is negligible.

Conclusion {#Sec14}
==========

We show that gentamicin clearance increases with body weight according to a power function with an exponent of 0.73. As we found that the current worldwide deployed dosing strategy of dosing on LBW or ABW may lead to lower exposure with increasing bodyweight, we propose the use of a dose nomogram on an allometric 'dose weight' \[calculated as 70 × (TBW/70)^0.73^; Table [3](#Tab3){ref-type="table"}\] for dosing gentamicin in (morbidly) obese patients \> 100 kg to obtain similar exposure across all body weights up to 215 kg.
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